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Background: Hedgehog signaling plays an important role in embryonic development, organogenesis and cancer.
In the adult liver, Hedgehog signaling in non-parenchymal cells has been found to play a role in certain disease
states such as fibrosis and cirrhosis. However, whether the Hedgehog pathway is active in mature healthy
hepatocytes and is of significance to liver function are controversial.
Findings: Two types of mice with distinct conditional hepatic deletion of the Smoothened gene, an essential
co-receptor protein of the Hedgehog pathway, were generated for investigating the role of Hedgehog signaling in
mature hepatocytes. The knockout animals (KO) were inconspicuous and healthy with no changes in serum
transaminases, but showed a slower weight gain. The liver was smaller, but presented a normal architecture and
cellular composition. By quantitative RT-PCR the downregulation of the expression of Indian hedgehog (Ihh) and
the Gli3 transcription factor could be demonstrated in healthy mature hepatocytes from these mice, whereas
Patched1 was upregulated. Strong alterations in gene expression were also observed for the IGF axis. While
expression of Igf1 was downregulated, that of Igfbp1 was upregulated in the livers of both genders. Corresponding
changes in the serum levels of both proteins could be detected by ELISA. By activating and inhibiting the
transcriptional output of Hedgehog signaling in cultured hepatocytes through siRNAs against Ptch1 and Gli3,
respectively, in combination with a ChIP assay evidence was collected indicating that Igf1 expression is directly
dependent on the activator function of Gli3. In contrast, the mRNA level of Igfbp1 appears to be controlled through
the repressor function of Gli3, while that of Igfbp2 and Igfbp3 did not change. Interestingly, body weight of the
transgenic mice correlated well with IGF-I levels in both genders and also with IGFBP-1 levels in females, whereas it
did not correlate with serum growth hormone levels.
Conclusions: Our results demonstrate for the first time that Hedgehog signaling is active in healthy mature mouse
hepatocytes and that it has considerable importance for IGF-I homeostasis in the circulation. These findings may
have various implications for mouse physiology including the regulation of body weight and size, glucose
homeostasis and reproductive capacity.
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Background
The Hedgehog signaling pathway, like that of other mor-
phogens, plays an important role in embryonic develop-
ment, organogenesis and tissue homeostasis. In the adult
stage, its activity is downregulated in most organs, but
can be reactivated in physiological and pathological pro-
cesses such as tissue regeneration and cancer. In the adult
liver, Hedgehog signaling is lower in parenchymal cells,
the hepatocytes, than in non-parenchymal cells where it
has been found to play a fundamental role in certain dis-
ease states such as fibrosis and cirrhosis. Whether the
Hedgehog pathway is active in mature healthy hepatocytes
and is of significance to liver function are controversial.
Findings
In order to approach these questions we used two types
of mice with distinct conditional hepatic deletion of the
Smoothened gene, an essential co-receptor protein of the
Hedgehog pathway. Knockout of this gene interrupted
the Hedgehog pathway only in hepatocytes. The knock-
out mice were healthy, but showed a slower gain of body
and liver weight. Alterations in the expression of Hedgehog
signaling components revealed the functional activity of
this pathway in the liver. Strong alterations in gene ex-
pression were also observed for insulin-like growth factor-I
(IGF-I) the serum level of which correlated well with
body weight.
Conclusions
Our results demonstrate for the first time that Hedgehog
signaling is active in mature mouse hepatocytes and that
it has considerable importance for IGF-I homeostasis
in the circulation. These findings may have various impli-
cations for mouse physiology including the regulation of
body weight and size, glucose homeostasis and reproduct-
ive capacity.
Background
Hedgehog (Hh) signaling is known to play an important
role in embryonic development, organogenesis and can-
cer [1,2]. Secreted Hh ligands (Sonic hedgehog (SHH),
Indian hedgehog (IHH) and Desert hedgehog (DHH))
influence on target cells via autocrine, paracrine or even
endocrine-like ways. They bind to PTCH1 and PTCH2
receptors and alleviate Patched-mediated suppression of
Smoothened (SMO), a putative seven-transmembrane
protein with features of a G-protein coupled receptor
[3,4]. Activated Smo induces a number of downstream
reactions, finally leading to stabilization of Gli transcrip-
tional factors, their translocation into nucleus and tran-
scription of Hh-dependent genes. In vertebrates three
Gli genes are present. GLI1 is acting predominantly as a
transcriptional activator of Hh target genes, while GLI2and GLI3 may act as both activators and repressors de-
pending on Hh activity [5,6].
In adult tissues Hh signaling is commonly downregu-
lated and may be reactivated only in certain types of cancer
[7,8]. Like for other morphogens, however, Hh signaling in
adult tissues frequently shows activity gradients that are
involved in maintenance of tissue homeostasis. Well stud-
ied examples are the maintenance of the specific pheno-
type of gastric and intestinal epithelium [9,10] and the fate
of adipose tissue [11,12]. In the adult liver, active Hh sig-
naling has been observed in some non-parenchymal cells
namely hepatic stellate cells (HSC) and cholangiocytes
[13,14], where it plays a fundamental role in maintaining
the normal phenotype of these cells but also during their
activation in certain disease states such as fibrosis and
cirrhosis [14]. Under diseased conditions also stressed or
dying hepatocytes (e.g. when ballooning in severe liver
steatosis) were described to secret high amounts of Shh
which appears to act as a major signal for inducing alter-
native regenerative pathways via stem cell populations
[15-17]. However, whether the Hh signaling pathway is
active in healthy, mature hepatocytes and relevant to nor-
mal liver function remains controversial [13,18]. On the
one hand, a significant contribution of Hh signaling to the
regulation of liver function has been denied because of the
low expression level of the respective signaling compo-
nents in mature hepatocytes compared with certain types
of liver cancer cells or even non-parenchymal cells such as
HSC or cholangiocytes [13,14]. On the other hand, theor-
etical considerations based on analogy with other tissues
considerably support the hypothesis that Hh signaling
might indeed play a fundamental role in controlling liver
function [18].
In order to clarify the important question of whether
Hh signaling is active in healthy, mature hepatocytes, we
have chosen two independent types of transgenic mice
with conditional hepatocellular ablation of Smoothened,
a bottleneck component of the Hh pathway [19], to inter-
rupt Hh signaling in hepatocytes. These mice should be
optimally suited for investigating the functional relevance,
if any, of low Hh signaling in these cells. To exclude any
aberrant findings due to damaged or immature hepato-
cytes we carefully checked the histological integrity of
the livers after knockout of Smo including the integrity
and phenotype of the hepatocytes in situ. A second
method for gaining insight into the functional relevance of
Hh signaling in hepatocytes was to use RNAi experiments
in vitro for modulating (i. e. inhibiting or activating) Hh
signaling and monitoring the altered transcriptional and
functional output. For that purpose a high purity of
the cultured hepatocytes was guaranteed. Using these ap-
proaches and various analytical techniques we were able to
demonstrate for the first time to our knowledge that Hh
signaling is active in mature hepatocytes and contributes
Matz-Soja et al. Cell Communication and Signaling 2014, 12:11 Page 3 of 15
http://www.biosignaling.com/content/12/1/11to the regulation of IGF-I and IGFBP-1 protein serum
levels in mice.
Results
Generation and phenotypic characteristics of Smo-KO
mice
For investigating the influence of the Hedgehog signaling
pathway on liver function, hepatocyte-specific ablation
of Smo, a bottleneck component of Hh signaling [19],
seemed a suitable approach. In the first type of trans-
genic mice, conditional ablation of Smo in liver epithelial
cells was induced by mating Smoflox/flox and Alfp-Cre
mouse lines (Additional file 1: Figure S1A-C). The result-
ing double transgenic homozygous Smo−/− mice are ab-
breviated as SAC-KO mice. Alfp-Cre mice [20] have been
successfully used for liver-specific knockout studies [21].
In agreement with these studies, Cre-recombinase could
be detected by immunohistochemistry in all liver epithelial
cells (hepatocytes and cholangiocytes) (Additional file 1:
Figure S1D), and only the recombined Smo alleles could
be detected in the livers of homozygous mice after
12 weeks (Additional file 1: Figure S1E). As expected, sig-
nificant loss of Smo expression was found in the liver and
in isolated hepatocytes, and no changes were found in the
heart, lung, spleen, adipose tissue or kidney (Additional
file 1: Figure S1F).Figure 1 Phenotypic features induced by hepatocyte-specific ablation
SAC mice and (B): female SAC mice show two WT mice (left) and two KO
squares) (n = 4) and SAC-KO (open circles) (n = 5) mice and (D): female SAC
Values are presented as the means ± SEM; *, p < 0.05.The first visible phenotype of the SAC-KO mice was
evident immediately after birth; the mice were small in
size compared to their WT littermates (Figure 1A, B).
At 30 days after birth, when the offspring were separated
from their dams, body weight was significantly reduced
in both male and female homozygous SAC-KO mice
compared to gender-matched WT mice (Figure 1C, D).
Weight gain in the transgenic males paralleled that in
WT males up to the age of 12 weeks, after which it ap-
peared to progress at a slightly lower pace in transgenic
female mice during the same period of time (Figure 1D).
Interestingly, the weight of the heterozygous SAC-KO
mice (Smo+/−) was significantly different from that of both,
the WT littermates and the homozygous mice (Additional
file 2: Figure S2A,B) indicating that the loss of each Smo
allel caused a distinct drop of body weight. The age of
12 weeks was chosen for further investigations because
the animals were fully mature at this time point, which
allowed the proper isolation of the mature hepatocytes es-
sential for this study.
Generally, the SAC-KO mice were healthy and their
behavior was inconspicuous. They showed slightly re-
duced blood glucose levels in the postprandial state and
had significantly lower plasma insulin levels (Table 1).
Histological examination of the liver revealed a normal
lobular architecture, indicating that Smo ablation did notof Smoothened in transgenic SAC mice. Photographs of (A): male
mice (right). Comparison of body weight of (C): male SAC-WT (black
-WT (black squares) (n = 3) and SAC-KO (open circles) (n = 4) mice.
Table 1 Liver parameters and serum activities of male and female SAC-WT and SAC-KO mice
Male mice SAC-WT n SAC-KO n p value (MWU-test)
Liver weight (g) 1.65 ± 0.09 6 0.95 ± 0.03 14 0.001**
Liver-body-weight ratio (%) 5.58 ± 0.16 6 4.38 ± 0.14 14 0.001**
ALAT (μkat/l) 1.64 ± 0.48 3 2.47 ± 0.37 4 0.228
ASAT (μkat/l) 8.07 ± 3.97 3 6.82 ± 1.83 4 1.000
GLDH (μkat/l) 0.35 ± 0.08 3 1.93 ± 0.58 4 0.057
Insulin (pmol/l) 160.53 ± 43.84 7 44.86 ± 11.97 5 0.0101*
Glucose (mMol/dl) 8.12 ± 0.48 5 7.22 ± 0.40 7 0.34
Female mice
Liver weight (g) 1.29 ± 0.06 17 1.10 ± 0.06 8 0.724
Liver-body-weight ratio (%) 5.82 ± 0.18 17 4.91 ± 0.16 8 0.001**
ALAT (μkat/l) 1.48 ± 0.50 6 2.47 ± 0.37 6 0.228
ASAT (μkat/l) 4.80 ± 0.44 6 7.07 ± 1.10 6 1.000
GLDH (μkat/l) 0.54 ± 0.10 6 1.04 ± 0.28 6 0.057
Insulin (pmol/l) 98.24 ± 10.68 10 56.73 ± 5.89 8 0.0021**
Glucose (mMol/dl) 7.19 ± 0.24 9 6.22 ± 0.40 10 0.079
Determination of body weight and liver parameters at the age of 12 weeks. Values represent means ± SEM; *, p < 0.05; **, p < 0.01.
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leading to a smaller size. Liver weight was significantly
reduced by approx. 40% in male SAC-KO mice (Table 1),
and the liver weight/body weight ratio dropped from
5.6% in WT mice to 4.4% in SAC-KO mice. In female
mice, similar alterations were observed, except for a smaller
difference in total liver weight (Table 1). Apart from the
slower liver weight/body weight ratio compared to SAC-
WT mice, there were no indications of overt liver damage
in the SAC-KO mice in both genders. Accordingly, no sig-
nificant differences could be observed in serum activities
of ASAT, ALAT and GLDH between SAC-WT and SAC-
KO mice (Table 1). Furthermore, comparing the expres-
sion levels of different marker genes for hepatic stellate
cells (HSC) and myofibroblasts (Gfap, Acta2) or Kupffer
cells (Emr1), in liver tissue from SAC-WT mice and
SAC-KO mice revealed no major changes in the cellular
composition (Figure 2A, B). This could be confirmed by
immunohistochemistry as exemplified by the distribution
of GFAP which was found only in HSC and cholangiocytes
(Figure 2C). Only the general marker of non-parenchymal
cells, PKM2 [22] seemed to be slightly induced in hepato-
cytes from SAC-KO mice (Figure 2D).
Influence of Smoothened ablation on Hedgehog pathway
components in hepatocytes in situ and ex vivo
To analyze hepatocellular Hh signaling, the expression
of several components involved in the pathway was de-
termined by qRT-PCR in freshly isolated hepatocytes
(Figure 3). Purity of the hepatocyte preparation, prepared as
described in Materials and Methods, was carefully checked
using the markers for hepatocytes (Arg1, Gck, Gls2, Ldha,Krt8, Krt18) (Additional file 3: Figure S3A,B). For non-
parenchymal cells like hepatic stellate cells, myofibroblasts
and Kupffer cells we used the markers shown above. Fur-
thermore we used markers for cholangiocytes (Krt19) and
endothelial cells (Cd34) (Additional file 3: Figure S3C,D). In
particular, contamination of hepatocyte preparations by
cholangiocytes was excluded as described previously [23].
Apart from the expected loss of Smo expression in
hepatocytes, the mRNA level of Ihh was significantly
downregulated, whereas Boc, Cdo and Ptch1 were signifi-
cantly upregulated (Figure 3A, B). The expression levels
of Shh, the inhibitor Hhip1 and components acting fur-
ther downstream, such as Fused and Sufu, were not sig-
nificantly affected (Figure 3C). Of the three members of
the Gli family of zinc-finger transcription factors, Gli1
and Gli3 were strongly downregulated (p < 0.05, n = 7),
whereas Gli2 appeared to be less affected (Figure 3D).
These results were comparable in female mice (not
shown) and clearly indicate that Hh signaling is active in
mature hepatocytes. These findings are in close agreement
with those in other cells challenged by Smo knockout [24].
Notably, Ihh expression appears to be characteristic of
healthy hepatocytes, whereas Shh is expressed by damaged
hepatocytes [16].
By immunohistochemistry it was possible to demon-
strate that indeed hepatocytes in situ stained positive for
IHH and GLI3 protein in the cytoplasm and the nuclei,
respectively (Figure 3E, F). Interestingly, staining for
IHH showed a pronounced pericentral distribution. In
livers of SAC-KO mice both proteins were downregu-
lated resulting in a weaker cytoplasmic staining (IHH) or
a loss of nuclear staining (GLI3) (Figure 3F).
Figure 2 Expression of markers for non-parenchymal cells in transgenic SAC mice. qRT-PCR analyses of (A): Acta2, Gfap and Emr1;
(B): Pkm2, Krt19 and Cd34 in liver tissue of 12 weeks old male SAC-WT (white bars) (n = 13) and SAC-KO (black bars) (n = 11) mice. Values
are presented as the means ± SEM. Immunohistochemistry in liver sections from male SAC-WT and SAC-KO mice of (C): GFAP (present
only in HSC’s), (D): PKM2 (Is present in all non-parenchymal cell types. Hepatocytes in SAC-KO mice show a very light cytoplasmic staining).
Bar: 100 μm and 20 μM.
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proteins of the IGF axis
Hepatocytes are the major source of circulating IGF-I in
many species including mice [25]. Because we have re-
cently hypothesized that IGF-I might be a possible target
of Hh signaling in these cells [18], we set out to evaluate
the expression of IGF-I and other members of the IGFaxis in hepatocytes freshly isolated from WT and SAC-
KO mice.
The expression levels of Igf1 mRNA and Igfbp1 mRNA
were measured by qRT-PCR. As shown in Figure 4A and B,
males and females demonstrated a significant downregula-
tion of Igf1 by approximately 80% and 60%, respectively.
Igfbp1 mRNA was upregulated by approximately 3-fold in
BA
C
E
F
D
Figure 3 (See legend on next page.)
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Figure 3 Expression changes of Hedgehog signaling components. qRT-PCR analyses of hedgehog members in hepatocytes freshly isolated
from 12-week-old male SAC-WT (white bars) (n = 8-17) and SAC-KO (black bars) (n = 8-13) mice: (A): Smo, Ihh and Shh; (B): Boc, Cdo and Ptch1;
(C): Hhip1, Fu and Sufu, and the transcription factors (D): Gli1, Gli2 and Gli3. Values are presented as relative means ± SEM; *, p < 0.05, **, p < 0.01.
Immunohistochemical staining of (E): Indian Hedgehog and (F): GLI3 in liver sections from male transgenic SAC-WT and SAC-KO mice at the age
of 12 weeks. Scale bars: 100 μM; 50 μM and 25 μM.
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nor Igfbp3 changed significantly (Figure 4C, D). Determin-
ation of the levels of IGF-I protein in serum revealed
strong downregulation in males and females (Figure 4E, F),
whereas the upregulation of IGFBP-1 was significant only
in female mice.
Completely similar results were obtained with a second
transgenic mouse model, the SLC-KO mice (Additional
file 4: Figure S4). Deletion of Smo in these mice is indu-
cible by transient exposure to Doxycycline at any desired
age of the animals. When the Smo knockout was induced
at 8 weeks of age, the SLC-KO mice show an immediate
reduction in weight gain during the next 5 weeks, theFigure 4 Changes of IGF axis members in the liver and serum. Quanti
Igfbp3 mRNA levels in hepatocytes isolated from 12-week-old male SAC-WT
and female SAC-WT (white bars) (n = 7) and SAC-KO (black bars) (n = 5) (rig
the means ± SEM; *, p < 0.05. (E, F): Serum analyses of circulating IGF-I and
(n = 8) mice and female SAC-WT (white bars) (n = 11) and SAC-KO (black basame significant alterations of Gli3, Igf1 and Igfbp1 expres-
sion levels in isolated hepatocytes, and the corre-
sponding changes in IGF-I and IGFBP-1 serum protein
concentrations (Additional file 4: Figure S4). These find-
ings convincingly demonstrate that the consequences of
hepatocellular deletion of Smo are independent upon the
specific mechanisms for conditional expression of Cre re-
combinase and other characteristics of the two types of
transgenic mice.
Gli3 is a transcriptional activator of Igf1
To gain insight into the mechanism through which Hh
signaling might control the expression of Igf1 and Igfbp1,tative RT-PCR analyses of (A, B): Igf1 and (C, D): Igfbp1, Igfbp2 and
(white bars) (n = 7) and SAC-KO (black bars) (n = 7) (left diagrams)
ht diagrams) mice relative to that of β-actin. Values are presented as
IGFBP-1 in male SAC-WT (white bars) (n = 9) and SAC-KO (black bars)
rs) (n = 13) mice. Values are presented as the means ± SEM; *, p < 0.05.
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tured hepatocytes from C75BL/6-N mice. Because Gli1 and
Gli3 were significantly down-regulated in SAC-KO mice,
we wanted to know which Gli-factor is the predominantFigure 5 RNA interference, ELISA and ChIP experiments. (A): Relative e
in cultured hepatocytes of male C57BL/6-N mice in response to transfectio
(white bars) (n = 8) after 48 h of incubation. Values are presented as relative
and Igfbp1 determined by qRT-PCR analyses in cultured hepatocytes of ma
bars) compared to nonsense transfection (white bars) after 48 h (n = 10-12)
means ± SEM; *, p < 0.05; **, p < 0.01; ***, p < 0.001. (C): Relative expression
male C57BL/6-N mice in response to transfection of Gli3 siRNA (black bars)
72 h of incubation and relative expression of Igf1 and Igfbp1 in C57BL/6 N-
compared to nonsense transfection (white bars) (n = 8). Values are presente
analyses of secreted IGF-I and IGFBP-1 in cultured hepatocytes of male C57
(n = 6) compared to nonsense transfection (white bars) (n = 6) after 72 h of
(E): GLI3 binding site at −405 bp of the Igf1 promoter according to MotifMap
with GLI3 Antibody (black), Histone H3 Antibody as positive control (grey), anone responding immediately to the loss of Smo. As shown
in Figure 5A, downregulation of Smo by Smo siRNA re-
sulted in the significant decrease of Gli3mRNA level within
48 h, while that of Gli1 was decreased only by trend at thisxpression of Smo, Gli1, Gli2 and Gli3 determined by qRT-PCR analyses
n of Smo siRNA (black bars) (n = 8) compared to nonsense transfection
means ± SEM; *, p < 0.05. (B): Relative expression of Ptch1, Gli3, Igf1
le C57BL/6-N mice in response to transfection with Ptch1 siRNA (black
and 72 h (n = 5-6) of incubation. Values are presented as relative
of Gli3 determined by qRT-PCR analyses in cultured hepatocytes of
(n = 11) compared to nonsense transfection (white bars) (n = 11) after
hepatocytes after 72 h of incubation with Gli3 siRNA (black bars) (n = 8)
d as relative means ± SEM; *, p < 0.05; **, p < 0.01. (D): Supernatant
BL/6-N mice in response to transfection of Gli3 siRNA (black bars)
incubation. Values are presented as the means ± SEM; *, p < 0.05.
. (F): qRT-PCR analyses of precipitated DNA. DNA immunoprecipitated
d IgG as a negative control (white) calculated relative to input.
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experiments. First, we asked whether the downregulation
of Gli3 might be sufficient to account for the observed
changes in the expression of Igf1. As expected, transfec-
tion of cultured hepatocytes with Gli3 siRNA depleted the
Gli3 mRNA level by 80% (Figure 5C). The decrease in
Gli3 expression was paralleled by a significant decrease in
Igf1 mRNA (Figure 5C), which was in perfect agreement
with the results obtained in SAC-KO mice. Moreover, the
knockdown lead to a significant decrease in IGF-I protein
determined by ELISA in the culture medium after 72 h
(Figure 5D).
Second, we were interested in whether the upregula-
tion of Hh signaling causes the opposite regulatory re-
sponse by the Igf1 gene. In line with other studies [19],
the siRNA-mediated downregulation of Ptch1 gene ex-
pression was chosen to activate Hh signaling. Hepatocyte
transfection with Ptch1 siRNA resulted in significant and
selective downregulation of Ptch1 expression and signifi-
cant upregulation of Gli3 after 48 h (Figure 5B), reflecting
the known activation of the Hh pathway through the loss
of Ptch1 [26]. In addition, upregulation of the pathway
was also indicated by the upregulation of Gli1, Gli2 and
Hhip1 (Additional file 5: Figure S5B,D). Other Hh compo-
nents (e.g. Smo, Ihh, Shh, Fu and Sufu) showed no changes
in expression, when the pathway was activated via Ptch1
siRNA (Additional file 5: Figure S5A,C). When Igf1 ex-
pression was evaluated in these experiments, a significant
upregulation of Igf1 mRNA levels was observed that per-
sisted till 72 h (Figure 5B). Together, these results suggest
that Igf1 is a direct transcriptional target of the activator
function of GLI3. Data mining by MotifMap [27] provides
three different possible binding sites for Gli3 within the
range of −5000 bp upstream to 5000 bp downstream of
the transcription start site (Additional file 6: Table S5).
One of these located at −405 bp upstream with the se-
quence TGTGTGGTC shows the most promising features
(Figure 5E) and, thus, was selected for a chromatin immu-
noprecipitation (ChIP) analysis. As shown in Figure 5F
GLI3 binding to the selected sequence could definitively
be proven by the ChIP assay. Both, positive and negative
controls showed the expected results.
Collectively, our results from hepatocytes ex vivo
(SAC-KO mice) and in vitro clearly show that the activity
of the Hh signaling pathway in the liver is a major deter-
minant of circulating IGF-I levels. To date, hepatic Igf1 ex-
pression is considered to be primarily regulated by growth
hormone via STAT5 [28,29]. Interestingly, in our SAC
mice no correlation was found between the serum levels
of growth hormone (GH) and IGF-I (correlation coeffi-
cient = 0.2488; p = 0.4124) indicating that GH is not the
dominant regulator of IGF-I serum levels. Whether Hh
signaling acts independently of or interferes with GH sig-
naling in hepatocytes remains to be established.Gli3 represses the expression of Igfbp1 but does not
affect that of Igfbp2 and 3
In contrast to Igf1, the mRNA level of Igfbp1 was upregu-
lated in livers of SAC-KO mice (Figure 4C). Therefore, we
wanted to know whether siRNA-mediated knockdown of
Gli3 in cultured hepatocytes also results in an inverse re-
sponse of Igfbp1 mRNA in vitro. Indeed, an inverse
picture was found, characterized by the selective upregu-
lation of Igfbp1 expression in response to Gli3 knockdown
(Figure 5C). Likewise, the concentration of IGFBP-1 pro-
tein secreted into the culture medium increased signifi-
cantly after a 72 h cultivation period (Figure 5D).
Conversely, activation of the Hh pathway by Ptch1
knockdown resulted in significant downregulation of
Igfbp1 mRNA within 72 h (Figure 5B). Apparently, the
response here is slightly delayed, because at 48 h after
Ptch1 knockdown the effect is seen only by trend. Again,
there is a nice correspondence to the presence of several
binding sites for GLI3 in the Igfbp1 promoter region
(Additional file 6: Table S5). In contrast, modulation of
Hh signaling in vivo or of Gli3 activity in vitro did not
show any response at all on the mRNA level of Igfbp2
and 3, for which no GLI3 binding sites could be identi-
fied using MotifMap (data not shown).
Discussion
The results obtained with newly generated transgenic
mice with hepatocyte-specific conditional knockout of
Smo reported herein replenished by RNAi experiments
using primary hepatocyte cultures demonstrate for the
first time that Hedgehog signaling is active in healthy
mature liver parenchymal cells and has considerable im-
pact for liver function, and – via modulating liver-derived
endocrine factors – for the entire organism. Even though
we agree with published data [30] that the levels of Hh sig-
naling components are low in hepatocytes, complete abla-
tion of Smo at early or late stages of development as in
both, the SAC-KO and the SLC-KO mice, leads to several
characteristic phenotypic alterations: a) an obvious growth
retardation resulting in lower body size and weight gain,
b) a reduced liver/body weight ratio, and c) altered levels
of production of IGFI and IGFBP-1 by the liver. Further-
more, changes in the expression of some Hh components,
particularly of Patched1, were noted indicating the ex-
pected response to the interruption of the Hh pathway.
Likewise, the Gli transcription factors Gli1 and Gli3 were
significantly downregulated in vivo at the mRNA level.
The fact that knockdown of Smo in vitro resulted only
in significant downregulation of Gli3 mRNA is com-
patible with the well-known finding that Gli1 is a target
gene of GLI3 [31]. These findings provide a first proof of
principle for our recent hypothesis concerning the exist-
ence of a measurable activity of Hh signaling in mature
hepatocytes [18].
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ered to be mainly associated with hepatocellular damage
and resulting regenerative phenomena [17], we carefully
investigated molecular markers for damage and precur-
sors of hepatocytes, but found no overt signs of cell
death, of activation or relative shifts of non-parenchymal
cell populations, and of other changes of liver architec-
ture in the transgenic mice. Thus, there is certainly an
effective Hh signaling that is not associated with hepato-
cyte toxicity and/or replacement. Instead, zonation of the
liver seemed to be affected which is of utmost importance
for liver function [32,33]. For example, the production of
IHH was found to be restricted to pericentral hepatocytes
in control livers and was downregulated in SAC-KO livers
to an even smaller pericentral area (c.f. Figure 3E). These
findings are in line with reports that IHH is a target
gene of Wnt/beta-catenin signaling [34] and indicate
that the knockout of Smo affects Wnt/beta-catenin sig-
naling as predicted recently [18]. Details of this crosstalk
between the two morphogen signaling pathways are cur-
rently investigated.
Another major result of this study is the unequivocal
evidence that hepatocellular Hh signaling is involved in
controlling the IGF-I axis in the mouse. The observed
decreased levels of Igf1 mRNA in hepatocytes and of
IGF-I protein in serum are in line with the fact that
liver-derived IGF-I is the principle source of this hormone
in blood [35]. Mechanistically, our results from RNAi ex-
periments on cultured hepatocytes in vitro encompassing
downregulation of Hh signaling by Gli siRNAs and, con-
versely, upregulation by Ptch1 siRNA strongly suggest that
Hh signaling acts via the activator function of GLI3 in the
transcriptional control of Igf1. Indeed, two active GLI3
binding sites in the promoter region of the Igf1 gene
have already been identified by McMahon and co-workers
[36], while data mining by MotifMap [27] provides even
three different possible binding sites within the range
of −5000 bp upstream to 5000 bp downstream of the
transcription start site (Additional file 6: Table S5).
The sequence TGTGTGGTC located at −405 bp up-
stream of the transcription start site which we selected for
a ChIP analysis nicely fits with the consensus sequence for
GLI3 binding sites (Figure 5E). Binding of GLI3 to this se-
quence could definitively be proven by the ChIP assay,
while both positive and negative controls showed the ex-
pected results (Figure 5F).
The contribution of Hh signaling to Igf1 transcription
in liver and to the control of serum levels of IGF-I is a
novel finding reported for the first time. Hitherto,
transcription of the Igf1 gene was thought to be mainly
controlled by growth hormone mediated by dispersed
STAT5b-binding elements [28,29]. Our finding that in the
SAC mice the IGF-I serum level does not correlate with
growth hormone levels argues against an exclusive role ofgrowth hormone. Thus, it seems an important challenge for
endocrinologists to elucidate the interplay between these
two regulatory mechanisms influencing IGF-I levels. In par-
ticular, it remains to be determined whether regulation of
Igf1 expression by GLI3 affects its regulation by STAT5.
Further, we provide strong evidence that IGFBP-1 which
is also mainly produced in the liver [37,38] is also influ-
enced by hepatocyte Hh signaling via a Gli3-mediated
mechanism. So far, IGFBP-1 is known to be inversely reg-
ulated by insulin [39]. Though plasma insulin levels are
lower in SAC mice of both genders and, thus might con-
tribute to the changes in IGFBP-1 in vivo, our in vitro
results clearly show that the influence by Hh is independ-
ent of insulin. Since IGF-I and IGFBP-1 were found to be
inversely regulated by Smo knockdown it is tempting to
speculate that in the case of IGFBP-1 GLI3 may act in a
repressive manner, since GLI binding sites were predicted
in the promoter region of the IGFBP-1 gene (Additional
file 6: Table S5). This would be compatible with the
known fact that GLI3 has both repression and activation
domains depending on the activation status [8]. Thus,
GLI3 may suppress Igfbp1 expression following knock-
down of Gli3 when GLI3 is truncated to the repressor
form. However, the situation is not as clear as for the acti-
vating role in the case of IGF-I for two reasons: a) there
are no suitable antibodies available that recognize solely
the truncated repressor form of GLI3, and b) at present
it cannot be excluded that GLI3 acts via repression of
an as yet unknown activator of Igfbp1 expression (un-
published observation). Nonetheless, our results suggest
that GLI3 is an important mediator in the regulation
of Igf1 and Igfbp1 expression by Hh signaling in mouse
hepatocytes.
Since IGF-I is long known as an important growth fac-
tor with high impact on skeletal growth and body size
[40], it is tempting to ask whether the observed changes
in the IGF-I axis found in the SAC-KO mice are respon-
sible for the observed changes in body size and weight
gain of these mice. Although there is general agreement
that liver-derived IGF-I is the principle source of this
hormone in blood, its role for postnatal growth in mice re-
mains controversial [35,41,42]. Interestingly, the data ob-
tained in this study shows a clear correlation between
IGF-I levels in serum and body weight for male (correl-
ation coefficient = 0.8422; p = 0.0003) and for female (cor-
relation coefficient = 0.6814; p = 0.0026) mice (Additional
file 7: Figure S6A,B). Likewise, the correlation between
IGFBP-1 and body weight is highly significant also in fe-
male mice (correlation coefficient = −0.4834; p = 0.0493)
confirming earlier results obtained with mice overexpress-
ing IGFBP-1 [43]. To our surprise, however, there is no
such correlation for GH in both genders (correlation coef-
ficient = 0.3356; p = 0.2623 in males and correlation coeffi-
cient = 0.2747; p = 0.4136 in females) suggesting that
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and size in our mice are members of the IGF axis rather
than GH.
Apart from contributing to body size, the physiological
consequences of the modulation of the IGF axis in SAC-
KO mice may be manifold. Liver-derived IGF-I was
found to be important for normal carbohydrate and lipid
metabolism [41]. Particularly, IGF-I contributes to main-
tenance of normal glucose homeostasis and is necessary
for normal insulin sensitivity [44]. Likewise, IGFBP-1 is
recognized as an important regulator of glucose levels
and a potential marker for the metabolic syndrome [45].
Our findings that plasma insulin levels are decreased in
SAC-KO mice, while refeed glucose levels were slightly
decreased rather than increased generally reflect an import-
ant influence of hepatic Hh signaling on glucose homeosta-
sis mediated, at least in part, by modulation of the IGF axis.
However, since the effects of IGF-I and IGFBP-1 are oppos-
ite in nature [44,45], it is hard to draw conclusions about
the individual contribution of these factors in the context
of our transgenic mice.
Another important consequence of the altered hepatic
Hh signaling may concern the reproductive capacity.
Both, IGF-I and IGFBP-1 were found to interfere with
reproductive functions particularly in females [46,47].
Most interestingly, low IGF-I serum levels and/or upreg-
ulated levels of IGFBP-1 are associated with considerably
impaired fertilization or implantation [37]. Indeed female
SAC-KO mice show a strongly reduced reproductive cap-
acity in line with the effects ascribed to the alterations in
the IGF-I axis rather than with GH. The anatomical and
physiological aspects of this effect are currently investi-
gated in detail.
Conclusions
In conclusion, the results of this study, obtained using dif-
ferent transgenic mice with conditional hepatic knockout
of Smo, demonstrate for the first time that Hh signaling is
active in healthy mature hepatocytes and has considerable
impact on endocrine liver function. The consequences are
manifold and comprise phenomena as different as body
size and weight, glucose metabolism and homeostasis or
female fertility.
Materials and methods
Generation of transgenic SAC mice
Transgenic mice with hepatocyte-specific knockout of
Smoothend (Smo) were obtained by crossing Smoflox/flox
and Alfp-Cre lines (Additional file 1: Figure S1A-C).
After establishing the animals the general breading proto-
col was as follows: male mice: Smoflox/flox + Cre-recombin-
ase mated with female Smoflox/flox - Cre recombinase. In
agreement with the results of Kellendonk et al. [20], Cre-
recombinase could be detected by immunohistochemistryin all hepatocytes and cholangiocytes (Additional file 1:
Figure S1D).
Genotypes of the transgenic mice were identified by PCR
using DNA from tailtips. After birth mice were screened
for expressing the Smo wildtyp (Smo WT), the Smo floxed
(Smo flx.) allele and the Cre-recombinase by PCR. All
primers are listed in Additional file 6: Table S1.
Generation of transgenic SLC mice
Triple transgenic mice allowing conditional hepatocyte-
specific ablation of Smo in response to exposure to
Doxycycline (abbreviated SLC mice) were generated by
crossing the Smotm2Amc/J mice (Jackson Laboratories) pos-
sessing loxP sites on either side of exon 1 of the Smo gene
[48] with double transgenic LC-1/rTALAP -1 mice [49] (gen-
erously provided by Hermann Bujard). For inducing ablation
of Smo, SLC mice were grown up for 8 weeks under normal
conditions. Then, expression of Cre-recombinase was in-
duced by adding Doxycycline hydrochloride (2 mg/ml) to
the drinking water for a period of 10 days.
Maintenance of mice and feeding
Mice were maintained according to the German guide-
lines and local regulations for the care and safe use of
experimental animals in a pathogen-free facility in a
12:12 h LD cycle (permission numbers: TVV11/08; N05/
12; A19/11). Animals had free access to regular chow
(ssniff ® M-Z V1124-0 composed of 22.0% protein, 50.1%
carbohydrate, 4.5% fat; usable energy: 13.7 kJ/g; ssniff ®
Spezialdiäten GmbH, Soest, Germany) and tap water
throughout life. Before sacrifice (between 9 and 11 am),
mice were starved for 24 h and re-fed with regular chow
for 12 h, in order to obtain a synchronized feeding state.
Measurements in blood samples and cell
culture-supernatant
Blood samples were taken from the beating heart of
anesthesized mice. Serum activities of ASAT, ALAT, and
GLDH were measured with an automated analyser (Roche
modular) using standardized assays (Roche, Mannheim,
Germany). Blood glucose levels were determined using a
Blood Glucose Meter (Freestyle Mini, Abbot, Wiesbaden).
Insulin was detected in serum with an Elisa- Kit from
DRG Instruments (Marburg, Germany) (EIA 3439). IGF-I,
IGFBP-1 and GH, were detected in serum with Elisa-Kits
from Mediagnost (Reutlingen, Germany and Cell Applica-
tions (San Diego, USA).
To determine IGF-I and IGFBP-I in cell culture super-
natant we used Elisa-Kits from Boster Biological Technology
(Fremont, CA, USA).
Isolation and cultivation of primary hepatocytes
Primary hepatocytes from SAC mice were isolated by
collagenase perfusion of the liver as described [50]. Cell
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cells by differential centrifugation. Finally, hepatocytes
were suspended in Williams Medium E containing 10%
fetal calf serum and further additions as described [50,51],
and were plated onto 12-well plates precoated with collagen
type 1. After 2 h, serum-free medium was used throughout
cultivation.
To give an overview of the purity of our primary hep-
atocyte isolation we looked for the expression of typical
markers of mature hepatocytes like Arg1 (Arginase 1),
Gck (Glucokinase), Gls2 (Glutaminase 2 (liver, mito-
chondrial)), Ldha (lactate dehydrogenase A chain), Krt18
(Keratin 18) and Krt8 (Keratin 8). For the non-parenchymal
cell population (e.g. hepatic stellate cells, vascular smooth
muscle cells kupffer cells and cholangiocytes) we analyzed
Gfap (glial fibrillary acidic protein), Acta2 (actin, alpha 2,
smooth muscle, aorta), Emr1 (EGF-like module containing,
mucin-like, hormone receptor-like sequence 1), and Krt19
(Keratin 19). All genes were analyzed in SAC-WT and
SAC-KO material (Additional file 3: Figure S3A,B,C,D).
RNA preparation and quantitative real-time PCR (qRT-PCR)
Total RNA from hepatocytes, liver tissue and other organs
was extracted using TRIzol (peqlab, Erlangen, Germay).
RNA was reverse transcribed using oligo(dt) primers and
Proto Script M-MuLV First Strand cDNA Synthesis Kit
(New England Biolabs, Frankfurt am Main, Germany).
The resulting cDNA samples were then quantified for
each test gene using target gene-specific primers designed
using the online tools Universal Probe Library software,
Perl Primer and Primer 3. Primers are listed in Additional
file 6: Table S2. The levels of all mRNA transcripts were
determined in duplicate by qRT-PCR using the Light
Cycler® 2.0 Instrument and the Light Cycler® Fast Start DNA
Masterplus SYBR Green I (Roche, Mannheim, Germany).
Using the standard curve method, the absolute quantifica-
tion of specific PCR products for each primer set was per-
formed. For normalization, β-actin was amplified from
each sample.
RNA-interference
Smo-, Ptch1- and Gli3-specific siRNAs and respective
nonsense control siRNAs were purchased from Invitro-
gen, Darmstadt, Germany. Freshly isolated hepatocytes
were seeded at a density of 100000 cells per well of
12-well plates in normal culture medium containing 10%
FCS. After 4 h, serum-free medium was used and chem-
ically synthesized siRNAs (10 nmol for Smo and Ptch1,
25 nmol for Gli3) were transfected with Interferin from
peqlab, Erlangen, Germany, according to the manufac-
turer’s instructions. Sequences for siRNA primers are lis-
ten in Additional file 6: Table S3. Twenty-four hours
after transfection, the medium was changed and fresh
medium without siRNA was added. Changes in geneexpression were analysed by qRT-PCR at 48 h and 72 h
post-transfection.
Chromatin Immunoprecipitation (ChIP)
To determine the binding of the transcription factor
GLI3 to the Igf1 promoter region we used the Simple-
ChIP Plus Enzymatic Chromatin IP Kit (Agarose Beads)
(Cell Signaling, Erlangen, Germany) according to the
manufacturer’s instructions. Freshly isolated hepatocytes
from three male C57BL/6 mice were pooled, washed
and cross-linked with 37% formaldehyde. As positive ex-
perimental control the Histone H3 (D2B12) XP® Rabbit
mAb (#2729) was used whereas normal Rabbit IgG served
as negative control. The cross-linked GLI3 DNA complex
was precipitated with the goat anti mouse GLI3 antibody
(20 μg) (R&D Wiesbaden-Nordenstadt, Germany). The
quantification analysis was performed using qRT-PCR
with 5 μl of each DNA sample and specific primers listed
in Additional file 6: Table S4. Primer pairs for the putative
GLI3 binding site in the Igf1 promoter region were de-
signed using Primer-BLAST of NCBI [52]. The range of
interest in the promoter region (~ −405 bp) was obtained
by the MotifMap [27] analysis. The applicability of the pri-
mer pair was tested using the UCSC In silico PCR analysis
(http://genome.csdb.cn/cgi-bin/hgPcr). The desired Igf1
amplicon resulted in a 283 bp fragment. The primers for
β–actin were used to analyse the unspecific DNA-Antibody-
binding. Rpl30 primers (included in the SimpleChIP Plus
Enzymatic Chromatin IP Kit) were used as a positive con-
trol for the histone H3 antibody precipitation.
Immunohistochemistry
Immunohistochemistry on paraffin sections (3 μm) was
performed similarly as described [53]. After dewaxing and
rehydration sections for Cre-recombinase, IHH, GLI3 and
PKM2 staining were microwaved (3 × 5 min) in citrate buf-
fer (0.01 M sodium citrate, pH 6.0) for antigen retrieval.
For GFAP staining the slides were incubated for 4 min
with 0.1% Proteinase K and 0.1% Calcium for antigen re-
trieval. Endogenous peroxidase was destroyed by incu-
bation with 3% hydrogen peroxide in TBS (0.01 M
Tris-base, 0.9% NaCl, pH 7.6) for 10 min. To block un-
specific binding, slides for Cre-Recombinase, GFAP, IHH
and GLI3 staining were incubated for 30 min in 5% goat
serum (Sigma, München, Germany) and slides for PKM2
staining were incubated for 30 min in 10% horse serum
(Sigma, München, Germany). Primary antibodies were rabbit
anti Cre-recombinase (1:4000; Abcam, Cambridge, UK),
rabbit anti Indian Hedgehog (1:250, Abcam, Cambridge,
UK), rabbit anti GLI3 (1:250, GeneTex, Irvine, USA), rabbit
anti Gfap (1:1000, Dako, Hamburg, Germany) rabbit
anti Pyruvate Kinase muscle (1:500, Biomol, Hamburg,
Germany). To visualize IHH and GLI3 proteins the Dako
REAL™ EnVision™ Detection System, Peroxidase/DAB+,
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cording to the manufacturer’s protocol. Secondary anti-
body for Cre Recombinase, PKM2 and GFAP staining was
biotinylated goat anti-rabbit IgG (Millipore, Schwalbach,
Germany) used together with Extravidine (Sigma, München,
Germany). Diaminobenzidine and Aminotriazole were
used for POD staining as described [53]. Sections were
counterstaining with hematoxylin.
Statistical analysis
Values are expressed as means ± standard deviation of
the mean (SEM) and sample size (n) is given in each fig-
ure ore table. Statistical evaluation was performed using
the Mann–Whitney-U-Test for fresh tissue and hepato-
cytes and the wilcoxon matched pairs test for the siRNA
experiments in cultured hepatocytes. The null hypothesis
was rejected at the p < 0.05 (*), p < 0.01 (**) and p < 0.001
(***) levels. The Pearson correlation coefficients and the
related p-values for Pearson’s correlation were calculated
using the Statistics toolbox of MATLAB (The MathWorks
Inc., Natick, MA, USA).
Availability of supporting data
The data sets supporting the results of this article are
included within the article (and its additional files).
Additional files
Additional file 1: Figure S1. Generation of the transgenic mouse
model with hepatocyte-specific deletion of Smoothened. (A): Structure of
the Alfp-Cre vector construct. (B): The Smo locus with loxP sites on either
side of exon 1in the absence of Cre-recombinase activity. (C): The floxed
Smo locus lacking exon 1 in the presence of Cre-recombinase activity.
(D): Immunohistochemical detection of Cre-recombinase in liver sections
of SAC-WT and SAC-KO mice. Brown colour indicating Cre-recombinase is
present in hepatocyte and cholangiocyte nuclei (strong staining) and
cytoplasm (weak staining). Bar: 50 μm. (E): PCR analysis, using DNA
extracted from liver tissue of SAC-WT and SAC-KO mice yields a 600-bp
amplicon of wild-type Smo in different tissues SAC-WT (black bars)
(n = 7-20) and SAC-KO (white bars) (n = 7-20) mice determined by
qRT-PCR. Significant decrease of Smo mRNA relative to β-actin is detected
only in liver. Values are presented as means ± SEM; *, p<0.05.
Additional file 2: Figure S2. Phenotypic features induced by
hepatocyte-specific ablation of Smoothened in transgenic SAC mice.
Photographs of (A): male SAC wildtype SAC-WT (Smo+/+), heterozygous
SAC-KO (Smo+/-) and homozygous SAC-KO (Smo-/-) mouse. (B): Comparison
of body weight of 4, 8 and 12 weeks old male SAC-WT (Smo+/+) (white bars)
(n = 4-9), heterozygous SAC-KO (Smo+/-) (gray bars) (n = 8-9) and homozygous
SAC-KO (Smo-/-) (black bars) (n = 8-21) mice. Values are presented as the
means ± SEM; *, p<0.05; **, p<0.01; ***, p<0,001.
Additional file 3: Figure S3. Expression of markers for hepatocytes and
non-parenchymal cells in liver sections and isolated hepatocytes from
male transgenic SAC mice. qRT-PCR analyses of the expression of markers
Arg1 Gck, Gls2, Ldha, Krt8 and Krt18 in male (A): SAC-WT liver (white bars)
(n = 8) versus SAC-WT hepatocytes (hatched bars) (n = 7); (B) SAC-KO liver
(white bars) (n = 8) versus SAC-KO hepatocytes (hatched bars) (n = 8).
Non-parenchymal cell markers Acta2, Gfap, Emr1, and Krt19 in male;
(C): SAC-WT liver (black bars) (n = 8) versus SAC-WT hepatocytes
(checkered bars) (n = 8); (D): SAC-KO liver (black bars) (n = 8) versus
SAC-KO hepatocytes (chekered bars) (n = 8). *, p<0.05;***, p<0.01; ***,
p<0.001. Values are presented as the means ± SEM.Additional file 4: Figure S4. Physiological and molecular effect of
hepatocellular deletion of Smo in transgenic SLC mice. (A): Comparison
of body weight of female SLC-WT mice without Doxycycline (Dox.)
(white bars) (n = 17), SLC-WT mice with Dox. (gray bars) (n = 4) and
SLC-KO mice with Dox. (black bars) (n = 12) at 5 weeks after deletion of
Smo. Doxycycline was given at the age of 8 weeks for 10 days to induce
the Cre-recombinase expression as described in Materials and methods.
(B): Comparison of body weight of female SLC-WT mice (black squares)
(n = 8-14) and SLC-KO mice (open circles) (n = 8-10). Deletion of Smo was
induced at the age of 8 weeks. (C): qRT-PCR analyses of the expression of
Smo, Gli1, Gli2 and Gli3 in isolated hepatocytes from female SLC-WT mice
(white bars) (n = 5-15) and SLC-KO mice (black bars) (n = 5-16) at 5 weeks
after deletion of Smo. (D): qRT-PCR analyses of the expression of Igf1 and
Igfbp1 in isolated hepatocytes from female SLC-WT mice (white bars)
(n = 7) and SLC-KO mice (black bars) (n = 4) at k weeks after deletion of
Smo. *, p<0.05; **, p<0.01; ***, p<0.001. Values are presented as the
means ± SEM.
Additional file 5: Figure S5. Response of selected Hh pathway genes
to siRNA mediated knockdown of Ptch1. qRT-PCR analyses of (A): Smo,
lhh and Shh; (B): Ptch2 and Hhip1, (C): Fu and Sufu and (D): Gli1 and Gli2
in cultured hepatocytes of male C57BL/6N mice in response to transfection
with Ptch1 siRNA (black bars) (n = 7-8) compared to nonsense transfection
(white bars) (n = 7-8) after 48 h of incubation. Values are presented as
relative means ± SEM.
Additional file 6: Table S1. Primers for PCR genotyping of SAC mice.
Table S2: Primers for qRT-PCR analyses. Table S3: Primers for RNA
interference experiments. Table S4: Primers for Chromatin IP. Table S5:
Binding sites of Gli factors and Gli factor-dependent transcription factors to
the promoter region of Igf1 and Igfbp-1 in mouse determined by MotifMap.
Additional file 7: Figure S6. Correlation analyses of IGF-I serum
concentrations and body weight from male and female transgenic SAC
mice. Correlation analyses of IGF-I serum concentrations and body weight
from (A): male SAC-WT (black circles) (n = 7) mice and SAC-KO (open circles)
(n = 6) mice and (B): female SAC-WT (black circles) (n = 9) mice and SAC-KO
(open circles) (n = 8) mice. c = correlation coefficient; p = significance level.
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